Pfizer is a healthcare company manufacturing and marketing pharmaceutical, animal health and consumer products. Pfizer researchers and scientists are working to discover and develop new ways to treat and prevent life-threatening and debilitating illnesses like Alzheimer's disease and cancer, as well as to improve wellness and quality of life. 
The main task in transforming Pfizer is to discover and develop more new medicines for patients. However, moving a new medicine from concept to patient is arguably the riskiest, most expensive R&D process undertaken by any company in any industry, says the company.
Large-scale changes in how the company does business and delivers value are also part of the next-generation Pfizer with comprehensive efforts to streamline itself. The company also plans to return to ‘solid’ top- and bottom-line growth.
In 2008, Pfizer had revenues of $48bn and research and development expenses of $8bn.
In October 2009, Pfizer completed its acquisition of Wyeth for $68bn (€52bn). For more on this please see Pfizer completes $68bn acquisition of US pharma rival Wyeth on ICIS news.
ICIS Chemical Business magazine has unveiled the ICIS Top 100 Chemical Companies, with rankings based on 2008 sales.
A PDF of the ICIS Top 100 Chemical Companies is available for download on ICIS connect.
See the article and analysis of the ICIS Top 100 on ICIS news.
Key Personnel
Chairman and CEO: Jeffrey Kindler
Director: Dennis Ausiello
Director: Michael Brown
Director: Anthony Burns
Director: Robert Burt
Director: Don Cornwell
Director: William Gray
Director: Constance Horner
Director: William Howell
Director: Suzanne Johnson
Director: James Kilts
Director: George Lorch
Director: Dana Mead
Director: William Steere
Director: Stephen Sanger
Director: Frances Fergusson
Director: John Mascotte
(Updated October 2009)
Contacts
Pfizer Inc.
235 East 42nd Street
New York
New York 10017-5755
US
Tel: +1 212 573 2323
Fax: +1 212 573 7851
www.pfizer.com
Pfizer
Company Structure
Pfizer is a healthcare company with sites in more than 150 countries around the world. It is divided into two main business segments. The first is pharmaceutical, which includes treatments for cardiovascular diseases, infectious diseases, central nervous system disorders, diabetes, arthritis, urogenital conditions and allergies, as well as the manufacture of empty soft-gelatin capsules.
More about Pfizer Structure
Pfizer
Strategy & Financial Highlights
On 20 July 2009, a merger agreement between Pfizer and Wyeth was approved, under which Pfizer will acquire Wyeth in a cash-and-stock transaction. The combined company is believed will create one of the most “diversified companies in the global health care industry”, with product offerings in growing therapeutic areas, a strong product pipeline, and leading scientific and manufacturing capabilities. ICIS also provides you with key financial data listed in table form.
More about Pfizer Strategy & Financial Highlights
News:
Get news on Pfizer plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Search:
Find details on other chemical companies and suppliers with
ICIS search
Newsletters:
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Plants and projects:
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database